VIRGINIA RETIREMENT SYSTEMS ET Al Buys New Holdings in Avantor, Inc. $AVTR

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Avantor, Inc. (NYSE:AVTR) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 194,100 shares of the company’s stock, valued at approximately $1,922,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC raised its holdings in shares of Avantor by 119.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,187 shares of the company’s stock worth $29,000 after purchasing an additional 1,189 shares during the period. Strategic Wealth Investment Group LLC purchased a new stake in shares of Avantor during the 2nd quarter worth about $32,000. Los Angeles Capital Management LLC purchased a new stake in shares of Avantor during the 4th quarter worth about $32,000. Osaic Holdings Inc. increased its position in Avantor by 60.9% during the 2nd quarter. Osaic Holdings Inc. now owns 2,810 shares of the company’s stock worth $38,000 after purchasing an additional 1,064 shares in the last quarter. Finally, SJS Investment Consulting Inc. increased its position in Avantor by 1,599.7% during the 1st quarter. SJS Investment Consulting Inc. now owns 5,235 shares of the company’s stock worth $41,000 after purchasing an additional 4,927 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on AVTR. Sanford C. Bernstein began coverage on shares of Avantor in a research report on Friday, June 26th. They set a “market perform” rating and a $10.50 price target on the stock. Morgan Stanley increased their price objective on shares of Avantor from $10.00 to $14.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 30th. TD Cowen reissued a “hold” rating on shares of Avantor in a research note on Wednesday, July 15th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $13.00 target price on shares of Avantor in a report on Thursday, July 30th. Finally, Wolfe Research raised shares of Avantor from a “strong sell” rating to a “hold” rating in a research report on Thursday, July 30th. Two investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Avantor currently has a consensus rating of “Hold” and an average target price of $12.47.

Avantor Stock Performance

Avantor stock opened at $14.79 on Friday. The stock’s 50 day moving average price is $13.10 and its 200 day moving average price is $10.13. The firm has a market capitalization of $10.00 billion, a PE ratio of -17.60, a price-to-earnings-growth ratio of 11.23 and a beta of 0.89. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.18 and a current ratio of 1.78. Avantor, Inc. has a one year low of $7.26 and a one year high of $15.93.

Avantor (NYSE:AVTR) last issued its quarterly earnings data on Wednesday, July 29th. The company reported $0.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.02. Avantor had a negative net margin of 8.81% and a positive return on equity of 9.92%. The company had revenue of $1.69 billion during the quarter, compared to the consensus estimate of $1.61 billion. During the same quarter last year, the company earned $0.24 earnings per share. Avantor’s revenue for the quarter was up .5% on a year-over-year basis. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. As a group, sell-side analysts expect that Avantor, Inc. will post 0.81 EPS for the current fiscal year.

Avantor Company Profile

Avantor, Inc (NYSE: AVTR) is a global provider of products and services used in the life sciences, healthcare and advanced technology industries. The company supports research, drug discovery, biopharmaceutical production, clinical and diagnostic activities, and other laboratory-based applications.

Its offerings include laboratory chemicals and reagents, consumables, equipment, instruments, production materials and related services. Avantor also provides supply-chain, procurement and other technical solutions designed to help customers manage laboratory and manufacturing operations.

Avantor serves customers across pharmaceutical and biopharmaceutical companies, healthcare providers, academic and government institutions, medical laboratories and industrial businesses.